Rentschler Group

Activities: Manufacturing

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023

Exceptional capabilities in guiding therapies from early stage development through to market based on more than 50 years of biotech experience
Manufacturing

Rentschler Biopharma announces major client project for new US facility

State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year
Manufacturing

Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma

Rentschler Biopharma announces that Dr Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective 1 December 2023
Manufacturing

Rentschler receives MHRA approval for AAV vector facility

The CDMO has received a cGMP following an MHRA visit to its UK site, now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy
Drug Delivery

Rentschler partners with Ikarovec on treatment for ophthalmic disease

Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UK
Manufacturing

Rentschler Biopharma appoints Head of Digital Manufacturing and Automation

Before joining Rentschler Biopharma, Thomas aus dem Siepen worked for 16 years in management positions at Roche Diagnostics
Manufacturing

Rentschler awarded in CDMO Leadership Awards

The CDMO Leadership Awards Ceremony and Reception will be held in New York City on March 22, 2023
Subscribe now